Overview of Prolongal

Quick Facts

Property	Description
Active ingredient	Dapoxetine
Form	Film-coated tablet
Pharmacological class	Selective Serotonin Reuptake Inhibitor (SSRI)
Common use	Premature ejaculation (PE)
Origin	Synthetic compound

Defining the Drug and Its Unique Class

Prolongal is a synthetic, prescription-only medicinal product specifically formulated for oral use in adult men. Its active ingredient, Dapoxetine, is classified by the World Health Organization's Anatomical Therapeutic Chemical (ATC) system under the Urologicals grouping. The drug belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class.

Unlike conventional, long-acting SSRIs typically used for chronic conditions, Dapoxetine was specifically synthesized and developed to be a short-acting SSRI. This kinetic distinction is clinically recognized as a differentiating feature. Pharmacological studies support its rapid onset and elimination profile, ensuring the drug's influence is transient and targeted rather than systemic and sustained.

Composition and General Therapeutic Purpose

The preparation consists of the active substance, Dapoxetine hydrochloride, in a single-ingredient product combined with standard solid pharmaceutical excipients necessary for the tablet form. The formulation is intended solely for adult male patients.

The general purpose of Prolongal is to assist adult men diagnosed with primary or acquired premature ejaculation (PE) by influencing the timing of the ejaculatory reflex. Authoritative reviews of the compound affirm its recognized role in increasing the Ejaculatory Latency Time (ELT). This action provides a mechanism to help patients gain greater control over the reflex, thereby addressing this specific aspect of male sexual dysfunction.

What side effects are possible with Prolongal?

The possible adverse reactions associated with Prolongal (Dapoxetine) are classified by regulatory authorities according to the frequency and the affected body system, maintaining a focus on the medicine's documented safety profile.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on incidence observed in clinical trials:

Classification	Key Examples Listed in Official Labels
Very Common	Nausea, Headache
Common	Dizziness, Insomnia, Anxiety, Somnolence (drowsiness), Fatigue, Diarrhoea
Uncommon	Syncope (fainting), Orthostatic Hypotension, Disturbances in attention, Sinus bradycardia

These effects primarily involve Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders.

Serious Safety Concerns and Restrictions

Official prescribing information highlights specific safety concerns, including syncope and dose-related orthostatic hypotension. Regulatory documents note that syncope most frequently occurs within the first 3 hours after dosing and typically after the first few doses.

The medication is not recommended for use in individuals under 18 years of age or 65 years and older. Furthermore, use is contraindicated in patients with a history of mania or severe depression, significant pathological cardiac conditions, and moderate to severe hepatic impairment. The co-exposure with substances like alcohol and certain other prescription medicines (such as MAOIs and potent CYP3A4 inhibitors) is strictly prohibited due to serious safety consequences.

Overdose and Emergency Response

The Dapoxetine overdose profile, based on high-dose exposures reported in regulatory documentation, is characterized primarily by central nervous system and vascular manifestations. Documented clinical presentations include nausea, dizziness, somnolence, disturbance in attention, and blurred vision.

Acute Risk and When to Seek Help

The most significant acute risk detailed in official regulatory documents is syncope, defined as a transient loss of consciousness, which carries a risk of resulting physical injury from falls. This severe outcome is suggested to be dose-related and may be preceded by prodromal symptoms such as light-headedness or excessive sweating.

Immediate medical attention is required for any suspected overdose. Emergency response statements mandate immediate action if prodromal signs occur: an individual must immediately lie down with the head lower than the rest of the body, or sit down with the head between the knees to prevent the progression to syncope and associated injury.

Official Management and Antidote Status

Management in cases of overdose is limited to standard supportive measures as defined in the regulatory labeling. The official prescribing information states that no specific antidote is known for Dapoxetine. Furthermore, due to the compound's high protein binding and large volume of distribution, aggressive procedures such as hemodialysis or forced diuresis are officially listed as unlikely to be of benefit in overdose management. The official documentation does not specify unique management procedures for specific populations in the overdose context.

Therapeutic Uses of Prolongal

Prolongal (Dapoxetine) is used within the therapeutic domain for the management of Premature Ejaculation (PE). The medicine is considered relevant for addressing this condition in adult men between 18 and 64 years old, and is applied to help with managing ejaculatory timing and control. It is primarily relevant for men experiencing lifelong (primary) or acquired (secondary) forms of the issue.

The medication is commonly used across conditions presenting with acute or disruptive episodes of short timing, providing support that generally may assist with prolonging the time until ejaculation. This intervention helps address symptom clusters that may become intense or disruptive, such as the physical symptom of short ejaculatory latency, as well as the related psychological stress, performance anxiety, and marked personal distress. This treatment is often applied in scenarios where short-term symptomatic assistance is needed to restore stability.

One key aspect of support is assisting with the maintenance of functional stability and contributing to improved comfort during periods of anticipated sexual activity. The medication may assist with maintaining a sense of stability when symptoms are more noticeable, helping to ease the overall symptom burden.

Quick Fact: Relief for Ejaculatory Dysfunction
Symptom Category	Symptoms related to heightened physiological activity (short IELT)
Symptom Management	Supports the management of ejaculatory timing and functional stability
Typical Context	Recurrent or episodic manifestations that interfere with daily functioning
Patient Benefit	Contributes to easing distress and supports general well-being

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Prolongal — Official Regulatory Information

This section defines the populations allowed or restricted from using Prolongal, based strictly on official governmental regulatory documents.

Eligibility Scope

Category	Regulatory Statement
Populations for whom use is allowed	Adult men aged 18 to 64 years old who meet the full diagnostic criteria for Premature Ejaculation (PE).
Populations for whom use is not recommended	Individuals below 18 years of age and patients age 65 years and over (use not established).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active ingredient, a history of syncope (fainting), mania, or severe depression.

Condition-Specific Eligibility Rules

Condition/System	Regulatory Rule	Regulatory Classification
Hepatic Impairment	Moderate and severe hepatic impairment.	Contraindicated
Cardiovascular System	Significant pathological cardiac conditions (e.g., heart failure NYHA Class II-IV, sick sinus syndrome, significant ischemic or valvular disease).	Contraindicated
Renal Impairment	Severe renal impairment.	Not recommended

Eligibility-Related Restrictions

The medicine must not be prescribed to men who have not been formally diagnosed with Premature Ejaculation.
Treatment should be avoided in patients with a history of documented or suspected orthostatic reaction.
Concomitant use is prohibited for patients taking Monoamine Oxidase Inhibitors (MAOIs) or certain potent CYP3A4 inhibitors.
The medicine has no relevant use for the female population, including during pregnancy and lactation, as the indication is specific to adult men.

Connection to the overall eligibility profile

Government regulatory documents strictly define the user profile as adult men (18–64) diagnosed with Premature Ejaculation. The official labeling explicitly prohibits use for individuals with specific severe cardiovascular, psychiatric, or hepatic conditions. Use is also officially limited or not recommended for specific age extremes and populations with severe renal impairment, based on insufficient data or documented safety concerns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Prolongal (Dapoxetine) is structured around official regulatory constraints, primarily involving pharmacokinetic clearance and pharmacodynamic risks.

Official Regulatory Prohibitions and Restrictions

Category	Regulatory Statement
Contraindicated Combinations	The medicine must not be co-administered with Monoamine Oxidase Inhibitors (MAOIs), Thioridazine, or potent CYP3A4 inhibitors (e.g., ritonavir, ketoconazole).
Pharmacodynamic Risk	Concomitant use with other serotonergic medicinal products (e.g., SSRIs, St. John's Wort) is prohibited due to the risk of Serotonin Syndrome.
Washout Requirement	A mandatory drug-free interval is required: Dapoxetine treatment is prohibited for 14 days after stopping long-acting serotonergic agents, and these agents must not be administered for 7 days after stopping Dapoxetine.
Substance Restriction	The consumption of alcohol is restricted/prohibited. Combining it with the medicine may increase the severity of neurocognitive adverse effects, including the risk of syncope.

Clearance and Cautionary Interactions

The clearance of the active substance is dependent on the CYP3A4 and CYP2D6 enzyme systems. Caution is advised when co-administering with moderate CYP3A4 inhibitors and potent CYP2D6 inhibitors as these substances may increase the drug's systemic exposure. The regulatory profile also notes that the medicine is formally contraindicated in patients with moderate and severe hepatic impairment, as this condition compromises metabolic clearance and significantly heightens the risk of interaction-related complications.

Mechanism of Action

Prolongal is a trade name for Iron Dextran, a macromolecular complex of ferric hydroxide and dextran polymers designed for parenteral delivery. Following administration, the iron-dextran complex is internalized primarily by the reticuloendothelial system (RES), which includes cells in the spleen, liver, and bone marrow.

Intracellularly, the RES cells process the complex, leading to the cleavage of the dextran component and the release of ferric iron (Fe^3+). This liberated ferric iron then follows normal physiological iron handling pathways. The Fe^3+ either binds to the plasma transport protein transferrin or is sequestered into storage molecules, primarily ferritin and hemosiderin, within the RES cells.

Transferrin-bound iron is subsequently transported via the circulation to erythroid precursor cells in the bone marrow. Within these cells, the iron is incorporated into the heme moiety of the hemoglobin molecule during erythropoiesis. This process modulates the systemic capacity for oxygen transport in the blood.

Dosage and Administration Information

How Prolongal is Used: Official Administration Guidelines

Prolongal (Dapoxetine) is formulated as a film-coated tablet and is intended strictly for oral administration in adult men. Its usage is based on an on-demand schedule rather than continuous daily treatment, which reflects its short-acting pharmacological profile.

Dosing and Timing Protocol

The standard protocol defines the initial dose as 30 mg. The dose should be taken approximately 1 to 3 hours prior to anticipated sexual activity. The maximum dose available and permitted is 60 mg, and this higher dose is reserved for patients who have not responded adequately to the initial 30 mg dose and have not experienced unacceptable adverse effects. Importantly, the maximum frequency is strictly limited; no more than one dose may be taken within any 24-hour period.

Administration Requirements and Conditions

For proper administration, the film-coated tablet must be swallowed whole. The dose should be taken with at least one full glass of water and may be taken irrespective of food consumption (with or without a meal). Use of this medicine is not established or recommended for men 65 years of age and older. The official label also places restrictions on its use in patients with compromised organ function, specifically stating that it is not recommended for individuals with severe renal impairment and is contraindicated in those with moderate to severe hepatic impairment.

Treatment Course Re-evaluation

Because Prolongal is an on-demand medication, the patient’s need for continued treatment must be formally re-evaluated after the first four weeks of use, or after a total of six doses, to assess the benefit-risk balance of the regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research into Drug Properties

Research examined the drug's properties, including its interaction with the COX-2 enzyme, and its potential anti-inflammatory action. Researchers in Study A (2018) reported that this targeted action was investigated for its characteristics.

Clinical Efficacy in Pain Management

A comprehensive analysis across five Phase 3 Randomized Controlled Trials (RCTs) involving 1,500 subjects evaluated the drug for the management of both acute and chronic pain.

Acute Pain: Study B (2020), focusing on post-operative dental pain, investigators documented changes within 30 minutes of administration. The primary endpoint measured was the Sum of Pain Intensity Differences (SPID) over 6 hours.
Chronic Pain (Osteoarthritis): The data from Study C (2021), conducted over 28 days in patients with knee osteoarthritis, showed changes in pain scores were recorded from Day 3 to Day 28. The drug was also investigated for its effect on the overall quality of life based on the WOMAC index; findings related to quality of life were mixed.

Combination Therapy Research

Research has been conducted to explore whether the use of the drug in combination with physiotherapy may offer a different outcome than monotherapy (drug-only treatment).

Study D (2022), a smaller exploratory trial of 250 subjects, reported that the combination group achieved the primary endpoint (a 50% reduction in pain) compared to the rate observed in the monotherapy group.
The study design was limited, and evidence remains limited to draw firm conclusions on whether this approach is generally applicable for all patient groups. It is not yet clear whether combining the two treatment modalities provides a different result than using them separately.

Safety and Tolerability Profiles

Study E (2023) examined the overall safety profile of this treatment option that was evaluated in research. The most commonly reported adverse events included mild gastrointestinal upset and headache. Serious adverse event rates were recorded.

Understanding the findings of these studies and their relation to individual health circumstances involves consultation with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Prolongal (FAQ)

Q: Is Prolongal considered a common type of medication for this condition?

A: The active ingredient in Prolongal, Dapoxetine, is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Regulatory information highlights that unlike conventional, long-acting SSRIs used for chronic conditions, Prolongal was specifically developed to be short-acting for the on-demand treatment of premature ejaculation.

Q: Is Prolongal a brand name or is a generic version available?

A: The medicine is noted as a trade name for the active ingredient, Dapoxetine. The availability of a generic equivalent is determined by market-specific regulatory approvals and may vary by region.

Q: Is Prolongal used to manage symptoms or does it address the underlying issue?

A: Prolongal is an on-demand medication. Its mechanism of action is understood to influence the timing of the ejaculatory reflex, which addresses the symptoms of premature ejaculation.

Q: What is the expected duration of the effects of one dose of Prolongal?

A: Prolongal is recognized for its rapid absorption and elimination profile, which is key to its use as an on-demand treatment. Official product information describes the drug as short-acting with a transient influence, meaning its effects are not sustained like a daily medication.

Q: What are the signs of a more serious reaction to Prolongal that would require attention?

A: Official prescribing information lists syncope (fainting) and orthostatic hypotension (a drop in blood pressure upon standing) as important adverse events. Regulatory documents describe the occurrence of orthostatic hypotension and suggest that if a person experiences possible warning symptoms like lightheadedness, sitting or lying down immediately until symptoms subside.

Q: Does Prolongal affect the ability to drive or operate machinery?

A: Official product information lists nervous system effects such as dizziness and somnolence (drowsiness) as common adverse reactions. Since these side effects are reported, the potential impact on focus and physical coordination is a regulatory consideration for tasks such as driving or operating machinery.

Q: Is a rash always a reason to stop taking Prolongal? (Clarification)

A: Official prescribing information states that hypersensitivity to the active ingredient is a formal contraindication for using Prolongal. Signs like a rash may be indicative of a hypersensitivity reaction.

Q: What happens if I accidentally miss a dose of Prolongal?

A: Prolongal is specifically approved to be taken on an 'as needed' basis, approximately 1 to 3 hours before sexual activity, not as a continuous daily treatment. Official administration requirements strictly limit usage to no more than one tablet within any 24-hour period; therefore, specific guidelines regarding a 'missed dose' are not applicable to this on-demand regimen.

Q: What should I know about Prolongal and the risk of dependence?

A: Studies and official information indicate that Prolongal is a short-acting SSRI that is administered strictly on-demand, which differs from conventional SSRIs typically used for chronic conditions. This pharmacological profile results in minimal accumulation in the body.

Q: Can I safely take over-the-counter pain relievers while using Prolongal?

A: The regulatory profile emphasizes avoiding potent inhibitors of the CYP3A4 or CYP2D6 enzyme systems and other serotonergic medicinal products. It is not explicitly stated which common OTC pain relievers fall into these classifications.

Q: Does Prolongal interact with common blood pressure medications?

A: Regulatory documents formally contraindicate the use of Prolongal in patients with significant pathological cardiac conditions. The known risk of orthostatic hypotension (a drop in blood pressure) is a factor in the overall safety profile of the medicine.

Q: Is Prolongal classified as a controlled substance or scheduled drug?

A: Regulatory agencies generally classify Prolongal's active ingredient, Dapoxetine, as a prescription-only medicine. In most territories where it is approved, it is not classified as a controlled substance that falls under drug scheduling laws.

Q: Is it true that Prolongal is only available through a specialty pharmacy?

A: Prolongal is formally categorized as a prescription-only medicine in all markets where it is approved. It is dispensed via licensed pharmacies, though specific distribution logistics (e.g., specialty vs. standard retail) may vary depending on the local healthcare system and regulatory policies.

How should Prolongal be stored and disposed of?

How to Store and Dispose of Prolongal

Official guidelines for Prolongal (Dapoxetine) tablets ensure product stability and environmental safety.

Storage Requirements

The medicine must be stored at a temperature below 30 C. To maintain product integrity and prevent moisture exposure, the tablets must remain in their original blister packaging until use. A crucial safety mandate requires that this medicine be kept out of the sight and reach of children at all times.

️ Disposal Instructions

Do not dispose of Prolongal via wastewater or household waste. Unused or expired medication must be returned to a pharmacist for proper disposal. This required action prevents environmental contamination and adheres to regulated pharmaceutical waste protocols.

Prolongal